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Abstract 
Background 
Affymetrix GeneChips and Illumina BeadArrays are the most widely used commercial single 
channel gene expression microarrays. Public data repositories are an extremely valuable 
resource, providing array-derived gene expression measurements from many thousands of 
experiments. Unfortunately many of these studies are underpowered and it is desirable to 
improve power by combining data from more than one study; we sought to determine 
whether platform-specific bias precludes direct integration of probe intensity signals for 
combined reanalysis. 
Results 
Using Affymetrix and Illumina data from the microarray quality control project, from our 
own clinical samples, and from additional publicly available datasets we evaluated several 
approaches to directly integrate intensity level expression data from the two platforms. After 
mapping probe sequences to Ensembl genes we demonstrate that, ComBat and cross platform 
normalisation (XPN), significantly outperform mean-centering and distance-weighted 
discrimination (DWD) in terms of minimising inter-platform variance. In particular we 
observed that DWD, a popular method used in a number of previous studies, removed 
systematic bias at the expense of genuine biological variability, potentially reducing 
legitimate biological differences from integrated datasets. 
Conclusion 
Normalised and batch-corrected intensity-level data from Affymetrix and Illumina 
microarrays can be directly combined to generate biologically meaningful results with 
improved statistical power for robust, integrated reanalysis. 
Background 
In the clinical sciences, systematic review is a valuable tool to synthesise high-quality 
empirical evidence from independent investigations in order to determine a consensus view. 
Such reviews, or meta-analyses have greater statistical power to identify true effects from 
study-specific artefacts and, as such, are capable of identifying subtle effects that might be 
missed or deemed insignificant in smaller datasets. In the context of gene-expression 
analyses, meta-analysis of results from microarray studies has great potential, but also 
presents significant challenges due to differences between the platforms and analysis 
approaches employed in each study [1-5]. Direct integration of probe-level expression data 
from multiple studies is potentially even more powerful, but is further complicated due to 
differences in the conditions under which each dataset was generated, such as the 
amplification or labelling method, the scanner used or even just the date on which the 
samples were processed. A recent comprehensive review found that the aims of different 
microarray meta-analysis studies were quite distinct, with the majority combining p-values, 
effect size or ranked analysis, with only 27 % (51 studies) seeking to directly merge the data 
and most of these were studies used the same platform [1]. We and others have previously 
demonstrated that non-trivial systematic bias or ‘batch effects’ can occur within both 
Affymetrix GeneChips and Illumina Beadarrays [3,4,6,7], but that they can largely be 
removed from each with appropriate correction methods. 
Gene expression profiling has been applied to many areas of translational cancer research, 
including identification of new drug-targets, monitoring response to treatment, revealing 
mechanisms of resistance, and predicting prognosis [8]. Although the majority of datasets are 
now made publicly available, many studies are limited in size and therefore cannot accurately 
reflect the general population, as they lack statistical power [9,10]. A consequence of this is 
that gene signatures generated from a small cohort of patients (the ‘training set’), will never 
perform as well in subsequent cohorts (‘test sets’) which inevitably have subtle differences in 
composition of patient or tumour variables. We previously showed that combining several 
similar Affymetrix datasets leads to a greater overlap in differentially expressed genes and 
more accurate prognostic predictions [5]. Collection of clinical material often remains the 
rate-limiting step, particularly with valuable ‘window-of-opportunity’ studies that utilise 
matched before- and after-intervention samples from the same patient [6,11-14]. Due to the 
reduced patient-patient variation, these studies can be highly effective for identifying 
consistent gene-expression changes, such as the effects of (neoadjuvant) cancer treatment. 
The extensive patient- and tissue-diversity inherent in molecular studies of cancer, which 
often contribute to underpowered studies [9] and confounding [15], mean that it is currently 
not necessarily critical (or appropriate) to measure gene-expression at the greatest resolution 
or specificity now offered by exon-arrays and RNA-sequencing. Rather, it may be of greater 
utility to maximise the number of existing biologically independent observations by 
combining the growing numbers of datasets in the public repositories, instead of simply 
generating another small independent dataset with limited statistical power [8]. 
Previous comparisons of expression measurements derived from Affymetrix and Illumina 
platforms have reported, ‘generally consistent’ [16], ‘very high agreement’ [17] or 
‘correspondence across platforms was high’ [18]. However these studies are often based on 
titrated or technical replicates rather than clinical samples and have not sought to integrate the 
intensity-level data directly. Cross-platform analysis of microarray data has previously been 
shown to be possible and worthwhile, although this has normally been performed using 
transformed relative values [19], analogous to those from two-colour microarrays and have 
been shown to result in fold change compression [18]. 
Considering the fundamental differences in the design of the two platforms, it is not clear 
whether data derived from Affymetrix and Illumina microarrays can be reliably compared 
directly. In this study we demonstrate that it is possible to directly combine appropriate 
datasets at the intensity level to improve statistical power. We show that the inter-platform 
bias can be sufficiently reduced to expose previously obscured biological variation and that 
such data correction does not amplify meaningless noise in the results. Despite intrinsic 
differences between these technologies, suitably similar studies can be directly integrated for 
robust and powerful meta-analysis. 
Results 
Direct cross-platform integration of MAQC data 
The Microarray Quality Control (MAQC) consortium [18] investigated the reproducibility of 
microarray-derived gene expression measurements by assessing performance across 
platforms, chips, and processing sites using a titration of Universal Human Reference RNA 
(UHRR) and Human Brain Reference RNA (UBRR). We combined the complete MAQC 
Affymetrix and Illumina datasets by re-annotating probes on each platform in terms of their 
Ensembl gene targets (see Methods and Figure 1). As expected, sample A (100 % UHRR) 
replicates from the same platform were found to be more highly correlated with sample C (75 
% UHRR, 25 % HBRR) replicates than the other samples. This was also the case for sample 
B (100 % HBRR) and D (25 % UHRR, 75 % HBRR) replicates, reflecting their relative 
biological similarity (Additional file 1A). Without adjustment, correlations between the same 
samples (A, B, C, or D) processed on different platforms were much lower (R = 0.70-0.77) 
than the same samples processed only on the Illumina Beadarrays (R = 0.98-1.00; Figure 2A 
and Additional file 1A) or Affymetrix GeneChips (R = 0.99-1.00). 
Figure 1 Summary of the data analysis workflow to assess direct integration of Illumina 
and Affymetrix gene expression data. The same/similar processing steps were used 
wherever possible, Affymetrix in green, Illumina in blue 
Figure 2 Affymetrix and Illumina data from the Microarray Quality Control project 
can be directly integrated. A) Pairwise Pearson correlation heatmaps (left) demonstrate 
cross platform bias and the effects of three correction methods, mean-centering, distance-
weighted discrimination (DWD) and an Empirical Bayes method (ComBat). R values range 
from low correlation (red) to high correlation (white) through shades of orange and yellow 
reflecting the overall similarity of expression profiles based upon biological and platform-
specific variation. The shades of purple to pink indicate the samples (A = 100 % UHRR, 
B = 100 % HBRR, C = 75 % UHRR + 25 % HBRR, D = 25 % UHRR + 75 % HBRR). 
Samples are ordered by replicate and lab name rather than by platform. Green bars for 
Affymetrix samples and blue for Illumina samples. Boxplots of correlation coefficients 
within and between labs are shown in (Additional file 1. B) Cross-platform correction 
minimises technical variation whilst maintaining biological variation and differential 
expression. C) Venn diagrams demonstrate the overlap between the 1000 most differentially 
expressed genes between the MAQC UHRR and HBRR (A and B samples) using 
significance analysis of Microarrays (SAM) method with either Affymetrix (Green) or 
Illumina (Blue) alone, or Affymetrix and Illumina together (Purple) 
Adjusting for the platform differences using the mean-centring method [5] provided only a 
marginal improvement compared to uncorrected data, whilst the Distance Weighted 
Discrimination (DWD) method [20] suppressed not only the platform-specific bias but also 
legitimate biological variability between samples (Figure 2 and Additional file 1A). The 
greatest improvement was observed following correction by ComBat, a method that exploits 
variance moderation during data adjustment [21]. Similar correlations were found both across 
and within platforms, suggesting that whilst removing the platform bias, ComBat method 
retains legitimate biological variation between the biologically distinct samples (Figure 2, 
Additional file 1A). Another promising method, Cross-Platform Normalisation (XPN) [22], 
could not be evaluated with these data due to the small number of independent biological 
replicates. 
In addition to correlating expression values, we calculated variance estimates for each of the 
15,781 Ensembl genes probed by the two platforms at the inter-sample, inter-platform, inter-
laboratory, and inter-chip levels using a nested analysis of variance described in methods 
(Figure 2B). As expected, and in agreement with the correlation analysis, the difference 
between the platforms was responsible for the majority of the overall variance in raw (58 %), 
quantile-normalised (47 %), and mean-centered (44 %) expression data. Inter-platform 
variance was significantly reduced by both DWD and ComBat, to 15 % and 7 % of the total, 
respectively. Consistent with the correlation analysis, the DWD method also substantially 
reduced inter-sample variance, which is likely to obscure differences between the samples 
(Figure 2B and methods). Conversely, the ComBat method slightly increased inter-sample 
variance, potentially uncovering meaningful biological differences between the 
UHRR/UBRR titrations. 
To examine the effects of cross-platform integration on the identification of genes 
differentially expressed between UHRR and HBRR, we analysed Affymetrix and Illumina 
data both separately and as a combined dataset. Differential expression was assessed using 
the Significance Analysis of Microarrays (SAM) method [23], identifying the top 1000 
differentially expressed genes and comparing the resulting gene-lists, as described previously 
[5]. Analysis of the 60 combined Affymetrix plus Illumina HBRR and UHRR samples 
together, resulted in lower false discovery rates and a greater number of statistically 
significant differentially expressed genes (Additional file 1B) than when the Affymetrix or 
Illumina (15 ‘A’ and 15 ‘B’) samples were analysed separately. There were also many more 
overlapping genes in the combined analysis and either of the platforms following cross-
platform correction, again with ComBat performing best (Figure 2C). The overlap of 
differentially expressed genes identified by samples processed on either of the two platforms 
independently (15 ‘A’ and 15 ‘B’ samples) was also much more consistent following 
ComBat, than DWD or mean centering correction (Additional file 1C). Taken together, these 
results indicate that combining data across the two platforms increases specificity and reduces 
the number of predicted false positives, suggesting improved statistical power. 
Increasing statistical power through integration of clinical datasets 
In order to evaluate the feasibility of directly comparing intensity level gene expression of 
clinical samples processed separately on the two platforms, we first generated a new dataset 
of Illumina Beadarray data from RNA derived from breast tumour samples that were assessed 
as part of a larger published study using Affymetrix GeneChips [13,24,25] (Figure 3A). 
These samples comprised matched baseline, two-week, and three-month primary breast 
tumours from 6 patients with a clinical response to neoadjuvant Letrozole. As with the 
MAQC data, pairwise Pearson correlations of samples processed on the two platforms were 
significantly increased following correction with the ComBat method, which again 
outperformed mean-centering and DWD by maintaining variation between biologically 
independent samples (Figure 3B and Additional file 2A-C). A fourth method, cross platform 
normalisation (XPN) [22] generated similar results to ComBat, although Pearson correlations 
for the majority of matched samples across both platforms were marginally higher 
(Additional file 2A-C). In addition, a greater number of pairs of Affymetrix and Illumina 
samples clustered together with the XPN method than with ComBat (Additional file 2E). 
Figure 3 Clinical samples processed on Affymetrix and Illumina platforms. A) 
Experiment Layout of the overlapping 18 matched clinical breast cancer samples from 6 
patients from similar Affymetrix and Illumina datasets studying the of the effect of Letrozole 
in the neoadjuvant setting. B) Pairwise Pearson correlation heatmaps (left) from 18 matched 
clinical breast cancer samples from 6 patients demonstrate cross platform bias and the effects 
of three correction methods, mean-centering, distance-weighted discrimination (DWD), an 
Empirical Bayes method (ComBat) and cross platform normalisation (XPN). R values range 
from low correlation (red) to high correlation (white) through shades of orange and yellow 
reflecting the overall similarity of expression profiles based upon biological and platform-
specific variation. The inner diamond represents the matched samples from the two 
platforms. Each patient sample is numbered as untreated (−1), 14 days (−2) and 3 months 
(−3) post treatment. Uncorrected data is NOT shown (to show it on the same colour scale as 
the other plots would not demonstrate the differences between the correction methods) 
We next expanded the cross-platform dataset with 48 new Illumina baseline and matched 
three-month samples from 24 independent patients to give a total of 60 Illumina samples to 
compare with 60 Affymetrix samples from the original dataset. All patients and tumours had 
similar characteristics and were shown to clinically respond to 3 months of neoadjuvant 
Letrozole treatment with tumour ultrasound measurements showing a stable volume 
reduction of 70 % over the three-month period. The twelve samples common to both 
microarrays were retained (Figure 4A). It was necessary to correct for batch effects within the 
platforms due to date of sample processing using ComBat as described previously [3-5]. 
Without cross-platform correction, plotting the fold changes between baseline and three-
month samples across the two platforms results in reasonable concordance (R = 0.68), 
however following XPN correction we see a dramatic improvement in the correlation of fold 
changes (R = 0.99) demonstrating that XPN has greatly reduced the variation between both 
platforms while maintaining a sufficient range of highly-concordant fold changes to account 
for biological variability (Figure 4B). Multidimensional scaling (MDS) demonstrated that the 
samples common to the Affymetrix and Illumina datasets cluster together and that intra- and 
inter-platform batch effects have been minimised (Figure 4C). Prior to XPN correction 
samples from the Affymetrix and Illumina datasets form independent clusters, however after 
correction baseline samples from the same patient cluster closely together as do the three-
month samples from the same patient. XPN correction significantly reduces the bias between 
samples from different platforms, but the baseline and three-month samples from the same 
patients still cluster independently, indicating that the true biological differences (due to 
treatment) are maintained. The standard deviation across genes for all baseline or three-
month samples was higher in Affymetrix than Illumina, but was dramatically increased after 
combining the data. Correction with either ComBat or XPN reduced variation to a level 
similar to that seen in either dataset independently, further suggesting that gene-wise cross-
platform bias is reduced, while true biological variation is maintained (Additional File 2D). 
When all samples of the combined XPN-corrected dataset were clustered by a published list 
of genes identified as most changed in response to neoadjuvant Letrozole [13,24] the baseline 
and three-month samples clustered together regardless of platform (Figure 4D). 
Figure 4 Integration of partially overlapping Affymetrix and Illumina datasets. A) 
Relationship between the baseline and 3 month samples processed on Affymetrix and 
Illumina platforms. R = repeated samples processed on Illumina BeadChips B) Scatterplot 
demonstrating the fold changes between the Affymetrix and Illumina datasets before (grey) 
and after XPN correction (black). C) Multidimensional scaling plots before and after XPN 
correction demonstrating the relationship between overlapping samples (circles = baseline, 
squares = 3 months post treatment with Letrozole, open symbols = Affymetrix, filled 
symbols = Illumina, triangles = Illumina repeated samples, different colours represent 
different patients). D) Hierarchical clustering and heatmap based on published list of genes 
identified as most changed between baseline and 3 month samples in patients treated with 
neoadjuvant Letrozole. Colour bar indicates the platform the sample was processed on with 
Affymetrix in green and Illumina in blue. E) Effect of cross-platform Integration and 
correction on differential gene expression analysis. Plot shows the relationship between the 
estimated false discovery rate relative to the number of significant differentially expressed 
genes identified using SAM analysis of Affymetrix and Illumina datasets independently and 
when combined both before and after XPN correction. Venn diagrams showing the 
overlapping genes between the 1000 most differentially expressed genes using the SAM 
method are available in Additional file 3 
Increasing sample number by integration of the Affymetrix and Illumina datasets resulted in 
the identification of a greater number of significantly differentially expressed genes using 
pairwise SAM (i.e. there was greater consistency of the changes between baseline and three-
month samples from the same patients) at a given false discovery rate (Figure 4E). 
Interestingly, correction of the combined data by XPN showed only minor improvement 
compared with uncorrected data in a pairwise SAM analysis with an impressive 93.8 % 
overlap of genes (Additional file 3A). However, when a non-pairwise SAM method was used 
(i.e. two unmatched groups: (i) all baseline samples and (ii) all three-month samples), XPN 
correction of the integrated data was essential (Additional file 3B&C). There was an 
impressive 90 % overlap of common differentially expressed genes following XPN 
correction when comparing the baseline samples from one platform with the three-month 
samples from the other. By contrast, the overlap between baseline and three-month groups in 
each dataset (Affymetrix or Illumina) independently was only 42.4 % (Additional file 
3A&B). Finally, comparing the uncorrected Affymetrix baseline versus Illumina three-month 
samples (and vice versa) with the XPN-corrected equivalent resulted in a very poor overlap 
(12.1 %), indicating the importance of XPN correction for robust differential gene expression 
of cross-platform integrated datasets. 
Published Affymetrix and Illumina datasets can be successfully integrated 
Two publicly available non-subtype specific primary breast cancer datasets of comparable 
size and composition (Nadiri et al. [26] n = 153 on Illumina WG6v1 and Desmedt et al. [27] 
n = 198 on Affymetrix HGU133A) were assigned to molecular subtypes using centroids from 
the intrinsic gene signatures of Sorlie et al. (2003) [5], Parker et al. [28], and Hu et al. [29]. 
This was performed on each dataset independently and then both datasets were combined, 
both before and after XPN correction. Clustering the integrated data before correction 
resulted in two distinct clusters representing the two datasets, highlighting the platform-
specific systematic bias (Figure 5). Following XPN correction the integrated data clustered 
based on true biological differences with two clear clusters representing the basal/Her2 
intrinsic subtype and the luminal subtype for each of the intrinsic centroids (Figure 5). 
Assignment of molecular subtype was highly consistent (Sorlie: 96.6 %, Hu: 94.9 % and 
Parker: 96.6 %) between uncorrected and XPN-corrected datasets, further suggesting that the 
XPN correction method does not adversely affect the biological interpretation of the data. 
Figure 5 Comparison of primary breast tumour gene expression profiles generated on 
Affymetrix and Illumina platforms. The Nadiri et al. [26] study used Illumina WG6v1 
BeadChips, whilst the Desmedt et al. dataset [27] was generated with Affymetrix HG-U133A 
arrays. A) Before cross-platform correction. B) After XPN. Hierarchical clustering of 
tumours is based upon the 500 most variable genes (thumbnails show all genes). i) Subtypes 
were assigned by three methods Sorlie et al. (2003) [5], Parker et al. [28] and Hu et al. [29]. 
Red = basal, purple = ERBB2, blue = luminal A, light blue = luminal B, green = normal-like. 
Clusters of genes associated with the subtypes are highlighted as follows; ii) ERBB2 gene 
cluster, iii) luminal gene cluster, iv) basal gene cluster 
Once again, increasing sample number through integrating datasets results in a greater 
number of significantly differentially expressed genes, between the Sorlie et al. basal and 
luminal-A or the more subtle comparison of luminal A and luminal B subtype samples, at a 
given FDR (Additional file 4). Uncorrected integrated data performs poorly in comparison to 
the integrated data after XPN correction or indeed to either dataset independently. 
Discussion 
The biggest obstacles to the direct comparison of data obtained from different microarray 
platforms are differences in the sequence and the number of probes that target each transcript. 
Many studies simply use the most highly or variably expressed probe to represent a gene, 
despite evidence that some probes hybridise to multiple genes and others have out-dated or 
incorrect annotation [30-34]. Limiting integration of data to only those genes where the probe 
sequences are identical, or comparing measurements simply based upon the official gene 
symbol would severely restrict our ability to evaluate whether data from different platforms 
can be directly integrated. For this reason, probes were re-annotated in this study using 
alternative CDFs [32] for Affymetrix and a validated composite look-up list for Illumina [35]. 
The microarray quality control (MAQC) project declared that expression values generated on 
different platforms cannot be directly compared because unique labelling methods and probe 
sequences will result in variable signals for probes that hybridize to the same target [18]. 
However in the interests of making the best use of published data on valuable clinical 
material, we asked whether it would be reasonable to integrate Affymetrix and Illumina data 
in the interests of improving statistical power and unearthing true biological findings. It has 
previously been shown that robust classifiers developed using data generated from one 
platform can accurately predict the phenotype of samples assessed on a different platform 
[36]. In this study we demonstrate that it is possible to combine Affymetrix and Illumina gene 
expression data for meaningful integrative reanalysis. As we have previously demonstrated 
for either platform alone, integration of microarray data should only be performed with 
appropriately similar datasets [3-5], although exactly where the similarity threshold lies is an 
important consideration that is still to be determined. 
During our analyses we found the Distance Weighted Discrimination (DWD) method [20], 
which has been used for cross-platform normalisation in a number of published studies (cited 
by more than 50), inadequate in terms of its ability to remove technical noise and preserve 
biological variability. Perhaps this method is best suited to transformed data such as that 
generated by two-colour cDNA studies. We used relatively strict filter-thresholds in our 
analyses, including conservative detection p-values to limit the analysis to clearly expressed 
genes as a previous meta-analysis approach found low or intermediate expressing genes to 
have poorer inter-platform reproducibility than highly expressed genes [14]. Another recently 
published comparison of cross-platform normalization methods also found XPN to have the 
highest inter-platform concordance [37]. Like our study this focused on direct adjustment 
approaches, where the major batch effect (platform used) is clearly identifiable rather than 
surrogate variable analysis (SVA) approaches [38,39], which look at latent or unknown 
variables, such as when samples are processed on different days, in different groups or by 
different people. Direct integration approaches are only appropriate for small numbers of 
highly similar datasets specifically selected to answer clearly defined questions, as opposed 
to recent global survey-based approaches used to identify common tissues or expression 
profiles across all available datasets [40-42]. Whilst integrating data across platforms 
increases the number of samples, it also has an impact on the number of genes represented. 
Genes may be ‘lost’ at the reannotation stage if not present on both arrays. Therefore 
integration is a trade-off between increased sample numbers and decreased gene number. 
Sample numbers are perhaps the biggest factor in the reliability of microarray studies. Ein-
Dor et al. suggested that thousands of samples are needed to generate a robust gene list for 
predicting outcome in cancer [9]. The overlap of differentially expressed genes between 
single and integrated Affymetrix and Illumina datasets was found to be high, although it 
should be remembered that it has previously been demonstrated that greater biological 
reliability is seen between studies at the pathway, rather than individual gene level [8]. 
Conclusion 
In this study we sought to evaluate whether it is reasonable to directly combine appropriate 
Affymetrix and Illumina datasets for reanalysis. We found that despite fundamental 
differences in the technology, data from these platforms can legitimately be combined at the 
normalised and corrected intensity level, rather than the fold change level for robust 
reanalysis with improved statistical power than the original datasets alone. 
Materials and Methods 
Data generation 
Affymetrix gene expression data was generated from primary breast tumour core biopsies 
before, 10–14 days after and approximately 3 months following neoadjuvant Letrozole 
treatment as part of a previously described clinical study [13,25]. The research was carried 
out in compliance with the Helsinki Declaration, with all patients giving informed consent to 
be included in the study which had been approved by the local ethics committee (LREC; 
2001/8/80 and 2001/8/81). RNA was extracted, amplified and labelled as previously 
described [25], before hybridisation to HGU-133A GeneChips (Affymetrix) according to the 
standard protocol. RNA from a subset of 18 samples (baseline, 10–14 days and 3 month 
samples from 6 patients defined as clinical responders to treatment) used in the 
aforementioned study [13,25] was then amplified using the WT-Ovation FFPE System 
Version 2 (NuGEN), purified using the Qiaquick PCR Purification Kit (Qiagen), biotinylated 
using the IL Encore Biotin Module (NuGEN), purified using minElute Reaction Cleanup Kit 
(Qiagen) and quantified using a Bioanalyser 2100 with RNA 6000 Nano Kit (Agilent). cRNA 
was then hybridised to Human HT-12v3 expression Beadarrays (Illumina, Cambridge, United 
Kingdom) according to the standard protocol for NuGEN amplified samples. A new Illumina 
gene expression dataset was also generated from primary breast tumour core biopsies before, 
10–14 days after and approximately 3 months following neoadjuvant Letrozole treatment. 
RNA was extracted using the miRNeasy Mini Kit with RNAse Free DNAse treatment 
(Qiagen). RNA was then amplified, labelled, purified, quantified and hybridised as described 
above for the Illumina 18 sample subset. All raw gene expression files and clinical annotation 
generated in this study are publicly available from the caBIG supported Edinburgh Clinical 
Research Facility Data Repository (https://catissuesuite.ecmc.ed.ac.uk/caarray/). 
Published MAQC and breast cancer datasets 
Methods for the MAQC Illumina Human-6 Expression BeadChip (v1) and Affymetrix U133 
Plus 2.0 array hybridisations are provided in the original study [18]. The NCBI GEO 
accession is GSE5350. Publicly available primary breast cancer datasets [26,27] were 
downloaded datasets from NCBI GEO and ArrayExpress. Breast cancer subtypes were 
assigned using three signatures from Sorlie et al. (2003) [5], Parker et al. [28] and Hu et al. 
[29] as described previously [43]. 
Data processing and analysis 
All data was processed using the R/Bioconductor software and packages [44], see Figure 1 
for the workflow, scripts are available from the authors by request. A custom Chip Definition 
File (CDF) file [32] was used to map the Affymetrix data to Ensembl gene annotations and 
RMA implemented by the affy package used for normalisation. Illumina probe profiles were 
quantile normalised using the lumi package and mapped to Ensembl gene sequences using a 
composite list comprising mappings from reMOAT [35], BioMart and a custom BLAST 
sequence search of the online Ensembl gene database where there was agreement between at 
least two of the resources (Additional File 5). Where multiple Illumina probes represented an 
Ensembl gene the mean expression level was calculated. The data was then filtered using 
Illumina or Affymetrix probe detection P-values, removing probes that were undetected 
(p > 0.05 in the total minus 3 samples). 
A number of batch-correction and cross-platform normalisation methods were evaluated, 
including mean centering [5], ComBat [21], Distance Weighted Discrimination [20] and 
cross-platform normalisation (XPN) [22] in order to determine the most effective method for 
reducing the bias imposed by the different platforms. Principal component analysis and 
hierarchical clustering analysis was performed using Cluster [45]. Significance analysis of 
Microarrays (SAM) [23] pairwise differential gene expression analysis was performed using 
the siggenes package (R/Bioconductor). 
We applied a linear additive model to log-scale expression data to estimate the variances in 
the MAQC dataset. The variation introduced at a given level propagates additively 
throughout subsequent levels, allowing these variance contributions to be modelled. The total 
variance for a given gene was assumed to be the aggregate of individual contributions from 
the inter-sample, -platform, -laboratory, and -replicate variability. These contributions are 
assumed to be independent and randomly drawn from log-normal distributions and, as all 
factors meet in unique combinations a nested variance model is individually applied to each 
gene such that the model of the measured expression, Xijkl, of each probe is defined as 
Χijkl = μ + Αi + Bij + Cijk + Dijkl + εijkl.(i = 1,… ,s; j = 1,…,t; k = 1,…,u; l = 1,…,v) where μ is the 
geometric-mean expression of the gene from the given sample-type, Ai is the effect attributed 
to the i
th
 sample, Bij is the random effect of the j
th
 platform, Cijk is the random effect of the k
th
 
lab, Dijkl is the random effect of the l
th
 replicate hybridisation, and εij is the residual 
measurement error. Finally, s is the total number of samples, t is the number of platforms on 
which the samples were assessed, u is the number of labs processing the arrays, and v is the 
number of replicate samples in the corresponding platform processed in each lab. The 
variance of any given observation, Xijkl, is σ
2
A + σ
2
B + σ
2
C + σ
2
D + σ
2
; these components 
represent the inter-sample, inter-platform, inter-laboratory, and inter-replicate variance 
respectively. The estimation of σ2A σ
2
B, σ
2
C , σ
2
D, and σ
2
 is performed independently for each 
gene as stated in [46]. Models of this kind are formally defined in [47,48] and have 
previously been used to optimise gene-expression experimental design [49,50]. All variance 
estimates were performed using a REML procedure implemented in the nlme package in R 
[51,52]. 
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